EFFECT OF SECUKINUMAB VERSUS ADALIMUMAB BIOSIMILAR ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A RANDOMISED PHASE IIIB STUDY
Abstract: OP0059
Authors: X. Baraliakos et al.
Key content:
There is a lack of data on the effects of biologic drugs on radiographic progression in axSpA. SURPASS was a head to head study comparing Secukinumab with Adalimumab biosimilar in radiographic axSpA (r-axSpA). The authors report here the analysis of radiographic progression in this phase IIIb randomized trial. The primary outcome was no radiographic progression, defined as a modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) <0.5 at week 104. 859 patients were randomized to Secukinumab 150 or 300mg or Adalimumab biosimilar. Low radiographic progression at week 104 was found in all groups, with a percentage of no Rx progression in 66.1%, 66.9% and 65.6% respectively. In patients that had a least 1 syndesmophyte at baseline, 56.9%, 53.8% and 53.3% respectively, did not develop new syndesmophytes. There were no statistically significant differences between the groups.
Relevance:
This randomized controlled head to head trial shows that Secukinumab at 150mg and 300mg doses is as effective as Adalimumab in preventing radiographic progression and new syndesmophyte formation in r-axSpA patients.
